<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25600248</article-id><article-id pub-id-type="pmc">5054919</article-id><article-id pub-id-type="doi">10.1111/dom.12439</article-id><article-id pub-id-type="publisher-id">DOM12439</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letters</subject></subj-group></article-categories><title-group><article-title>Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus</article-title><alt-title alt-title-type="left-running-head">Davies et al.</alt-title></title-group><contrib-group><contrib id="dom12439-cr-0001" contrib-type="author" corresp="yes"><name><surname>Davies</surname><given-names>M. J.</given-names></name><xref ref-type="aff" rid="dom12439-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12439-cr-0002" contrib-type="author"><name><surname>Trujillo</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="dom12439-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12439-cr-0003" contrib-type="author"><name><surname>Vijapurkar</surname><given-names>U.</given-names></name><xref ref-type="aff" rid="dom12439-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12439-cr-0004" contrib-type="author"><name><surname>Damaraju</surname><given-names>C. V.</given-names></name><xref ref-type="aff" rid="dom12439-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12439-cr-0005" contrib-type="author"><name><surname>Meininger</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="dom12439-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="dom12439-aff-0001"><label><sup>1</sup></label><institution>Janssen Scientific Affairs LLC</institution><named-content content-type="city">Raritan</named-content><named-content content-type="country-part">NJ</named-content><country country="US">USA</country></aff><aff id="dom12439-aff-0002"><label><sup>2</sup></label><institution>Janssen Research and Development LLC</institution><named-content content-type="city">Raritan</named-content><named-content content-type="country-part">NJ</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Michael J. Davies, Janssen Scientific Affairs LLC, 1000 US Highway 202, Raritan, NJ 08869, USA.<break/>
E&#x02010;mail: <email>mdavies9@its.jnj.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2015</year></pub-date><volume>17</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/dom.2015.17.issue-4</issue-id><fpage>426</fpage><lpage>429</lpage><history><date date-type="received"><day>07</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>12</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-17-426.pdf"/><abstract id="dom12439-abs-0001"><p id="dom12439-para-0001">Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present <styled-content style="italic-in-any-context">post hoc</styled-content> analysis of pooled data from four placebo&#x02010;controlled phase <styled-content style="fixed-case">III</styled-content> studies assessed the effect of canagliflozin, a sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (<styled-content style="fixed-case">T2DM</styled-content>) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid &#x02265;475&#x02009;&#x000b5;mol/l (&#x0223c;8&#x02009;mg/dl)]. At week&#x02009;26, canagliflozin 100 and 300&#x02009;mg were associated with a &#x0223c;13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo&#x02010;subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of &#x0003c;360&#x02009;&#x000b5;mol/l (&#x0223c;6&#x02009;mg/dl) with both canagliflozin 100&#x02009;mg (23.5%) and 300&#x02009;mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with <styled-content style="fixed-case">T2DM</styled-content>, including those with baseline hyperuricaemia.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12439-kwd-0001">canagliflozin</kwd><kwd id="dom12439-kwd-0002">diabetes complications</kwd><kwd id="dom12439-kwd-0003">drug mechanism</kwd><kwd id="dom12439-kwd-0004"><styled-content style="fixed-case">SGLT2</styled-content> inhibitor</kwd><kwd id="dom12439-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Janssen Scientific Affairs, LLC</funding-source></award-group></funding-group><counts><page-count count="4"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12439</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:07.10.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="dom12439-sec-0001"><title>Introduction</title><p id="dom12439-para-0002">Concerns about the side effects associated with antihyperglycaemic medications, such as weight gain and hypoglycaemia, have led to the development of diabetes treatments with novel mechanisms of action <xref rid="dom12439-bib-0001" ref-type="ref">1</xref>. The kidney has been the focus of most recent efforts because of the significant role it plays in maintaining glucose homeostasis <xref rid="dom12439-bib-0002" ref-type="ref">2</xref>.</p><p id="dom12439-para-0003">Sodium&#x02010;glucose co&#x02010;transporter 2 (SGLT2) is a high&#x02010;capacity, low&#x02010;affinity glucose transporter found in the proximal convoluted tubule of the kidney, and accounts for the majority of glucose reabsorption <xref rid="dom12439-bib-0002" ref-type="ref">2</xref>. The use of SGLT2 inhibitors, such as canagliflozin, provides an insulin&#x02010;independent method of increasing urinary glucose excretion and improving glycaemic control in patients with type 2 diabetes mellitus (T2DM) <xref rid="dom12439-bib-0001" ref-type="ref">1</xref>. Probably linked to this mechanism of action, canagliflozin was associated with a higher incidence of certain adverse events (AEs) in clinical trials (e.g. genital mycotic infections, urinary tract infections, osmotic diuresis&#x02010;related AEs, volume depletion&#x02010;related AEs). Most of these AEs were mild or moderate in intensity and few led to discontinuations <xref rid="dom12439-bib-0003" ref-type="ref">3</xref>.</p><p id="dom12439-para-0004">In addition to reducing blood glucose levels, SGLT2 inhibitors have been reported to lower serum uric acid levels <xref rid="dom12439-bib-0002" ref-type="ref">2</xref>. Uric acid is a by&#x02010;product of metabolism that can be influenced by diet, breakdown of cellular material and impaired renal elimination. The build&#x02010;up of serum uric acid in the body can lead to an increase in uric acid crystals in various organs, which can result in gout or the formation of kidney stones <xref rid="dom12439-bib-0004" ref-type="ref">4</xref>. There is evidence of an association between elevated serum uric acid levels, also known as hyperuricaemia, and risk of renal and cardiovascular disease <xref rid="dom12439-bib-0005" ref-type="ref">5</xref>. Several studies have identified hyperuricaemia as a predictor of the development of metabolic syndrome, diabetes and hypertension <xref rid="dom12439-bib-0006" ref-type="ref">6</xref>. Patients with both T2DM and hyperuricaemia are at an increased risk of developing gout, kidney stones and vascular complications <xref rid="dom12439-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12439-bib-0007" ref-type="ref">7</xref>. In addition, studies have identified an association between serum uric acid levels and mortality risk in patients with T2DM <xref rid="dom12439-bib-0007" ref-type="ref">7</xref>.</p><p id="dom12439-para-0005">Given the various disorders associated with hyperuricaemia, lowering serum uric acid may be beneficial for patients with T2DM, who may have a higher risk of microvascular and cardiovascular disease. The aim of the present <italic>post hoc</italic> analysis was to further characterize the effects of canagliflozin on serum uric acid levels in both a pooled T2DM cohort and a subset of this cohort who had hyperuricaemia at baseline compared with placebo. In addition, the incidence rates of gout and kidney stones were evaluated across treatment groups in both cohorts.</p></sec><sec id="dom12439-sec-0002"><title>Methods</title><sec id="dom12439-sec-0003"><title>Pooled Data Source</title><p id="dom12439-para-0006">In a <italic>post hoc</italic> analysis, serum uric acid level changes were evaluated in pooled data from four randomized, phase III, multinational, 26&#x02010;week trials, where canagliflozin (100 or 300&#x02009;mg) was compared with placebo as monotherapy, or dual or triple combination therapy (add&#x02010;on to metformin, metformin and sulphonylurea, or metformin and pioglitazone) <xref rid="dom12439-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12439-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12439-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12439-bib-0010" ref-type="ref">10</xref>. A total of 2313 patients with T2DM were enrolled. Changes in serum uric acid levels were evaluated in the overall pooled cohort and in the subset of patients (n&#x02009;=&#x02009;115) in the pooled cohort whose baseline serum uric acid levels indicated hyperuricaemia [defined as serum uric acid level&#x02009;&#x02265;475&#x02009;&#x000b5;mol/l (&#x0223c;8&#x02009;mg/dl)]. Furthermore, attainment of serum uric acid levels of&#x02009;&#x0003c;360&#x02009;&#x000b5;mol/l (&#x0223c;6&#x02009;mg/dl), a common target for uricosuric agents, was assessed in the patients with hyperuricaemia <xref rid="dom12439-bib-0011" ref-type="ref">11</xref>. Inclusion in the <italic>post hoc</italic> analysis required a baseline serum uric acid measurement and &#x02265;1 post&#x02010;randomization serum uric acid measurement. Serum uric acid can be converted from mg/dl to &#x000b5;mol/l by multiplying by 59.48.</p></sec><sec id="dom12439-sec-0004"><title>Statistical Analyses</title><p id="dom12439-para-0007">The least squares mean percent change and least squares mean change from baseline in serum uric acid were calculated using an analysis of covariance model with treatment and study as factors and baseline serum uric acid as a covariate. Placebo&#x02010;subtracted differences are reported with 95% confidence intervals (CIs). Statistical comparisons between groups were not performed as they were not pre&#x02010;specified; therefore, no p values are reported. The safety analysis set included data regardless of rescue medication use. No missing data imputation was performed.</p></sec></sec><sec id="dom12439-sec-0005"><title>Results</title><p id="dom12439-para-0008">In the overall cohort, the mean patient age was 56.0&#x02009;years, glycated haemoglobin (HbA1c) 8.0%, body mass index (BMI) 32.1&#x02009;kg/m<sup>2</sup> and estimated glomerular filtration rate (eGFR) 88.1&#x02009;ml/min/1.73&#x02009;m<sup>2</sup>. In the cohort of patients with hyperuricaemia, the mean age was 54.5&#x02009;years, HbA1c 7.9%, BMI 35.9&#x02009;kg/m<sup>2</sup> and eGFR 75.9&#x02009;ml/min/1.73&#x02009;m<sup>2</sup>. Baseline demographics and clinical characteristics were generally similar across treatment groups within each cohort (Table <xref rid="dom12439-tbl-0001" ref-type="table-wrap">1</xref>), but the cohort with hyperuricaemia had a greater proportion of men and tended to have a higher BMI and lower eGFR compared with the overall cohort (Table <xref rid="dom12439-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="dom12439-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline demographic and disease characteristics of the overall pooled cohort and subset of patients with hyperuricaemia (baseline serum uric acid &#x02265;8&#x02009;mg/dl)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" id="dom12439-ent-0001" align="left" valign="bottom" colspan="1"/><th colspan="3" align="left" id="dom12439-ent-0002" valign="bottom" rowspan="1">
<bold>Overall pooled cohort (N&#x02009;=&#x02009;2313)</bold>
</th><th colspan="3" align="left" id="dom12439-ent-0003" valign="bottom" rowspan="1">
<bold>Subset of patients with</bold>
<bold> baseline hyperuricaemia (n&#x02009;=&#x02009;115)</bold>
</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12439-ent-0004" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Placebo</bold>
<bold> (n&#x02009;=&#x02009;646)</bold>
</th><th id="dom12439-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Canagliflozin </bold>
<bold>100&#x02009;mg (n&#x02009;=&#x02009;833)</bold>
</th><th id="dom12439-ent-0006" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Canagliflozin</bold>
<bold> 300&#x02009;mg (n&#x02009;=&#x02009;834)</bold>
</th><th id="dom12439-ent-0007" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Placebo</bold>
<bold> (n&#x02009;=&#x02009;37)</bold>
</th><th id="dom12439-ent-0008" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Canagliflozin</bold>
<bold> 100&#x02009;mg (n&#x02009;=&#x02009;40)</bold>
</th><th id="dom12439-ent-0009" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Canagliflozin</bold>
<bold> 300&#x02009;mg (n&#x02009;=&#x02009;38)</bold>
</th></tr></thead><tbody valign="top"><tr><td id="dom12439-ent-0010" align="left" valign="top" rowspan="1" colspan="1">Sex, n (%)</td><td id="dom12439-ent-0011" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12439-ent-0012" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12439-ent-0013" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12439-ent-0014" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12439-ent-0015" align="left" valign="top" rowspan="1" colspan="1"/><td id="dom12439-ent-0016" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12439-ent-0017" align="left" valign="top" rowspan="1" colspan="1">Male</td><td id="dom12439-ent-0018" align="left" valign="top" rowspan="1" colspan="1">334 (51.7)</td><td id="dom12439-ent-0019" align="left" valign="top" rowspan="1" colspan="1">408 (49.0)</td><td id="dom12439-ent-0020" align="left" valign="top" rowspan="1" colspan="1">404 (48.4)</td><td id="dom12439-ent-0021" align="left" valign="top" rowspan="1" colspan="1">21 (56.8)</td><td id="dom12439-ent-0022" align="left" valign="top" rowspan="1" colspan="1">26 (65.0)</td><td id="dom12439-ent-0023" align="left" valign="top" rowspan="1" colspan="1">27 (71.1)</td></tr><tr><td style="padding-left:10%" id="dom12439-ent-0024" align="left" valign="top" rowspan="1" colspan="1">Female</td><td id="dom12439-ent-0025" align="left" valign="top" rowspan="1" colspan="1">312 (48.3)</td><td id="dom12439-ent-0026" align="left" valign="top" rowspan="1" colspan="1">425 (51.0)</td><td id="dom12439-ent-0027" align="left" valign="top" rowspan="1" colspan="1">430 (51.6)</td><td id="dom12439-ent-0028" align="left" valign="top" rowspan="1" colspan="1">16 (43.2)</td><td id="dom12439-ent-0029" align="left" valign="top" rowspan="1" colspan="1">14 (35.0)</td><td id="dom12439-ent-0030" align="left" valign="top" rowspan="1" colspan="1">11 (28.9)</td></tr><tr><td id="dom12439-ent-0031" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) age, years</td><td id="dom12439-ent-0032" align="left" valign="top" rowspan="1" colspan="1">56.3 (9.8)</td><td id="dom12439-ent-0033" align="left" valign="top" rowspan="1" colspan="1">55.9 (10.1)</td><td id="dom12439-ent-0034" align="left" valign="top" rowspan="1" colspan="1">59.1 (9.6)</td><td id="dom12439-ent-0035" align="left" valign="top" rowspan="1" colspan="1">55.9 (9.7)</td><td id="dom12439-ent-0036" align="left" valign="top" rowspan="1" colspan="1">54.4 (9.4)</td><td id="dom12439-ent-0037" align="left" valign="top" rowspan="1" colspan="1">53.5 (10.0)</td></tr><tr><td id="dom12439-ent-0038" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) HbA1c, %</td><td id="dom12439-ent-0039" align="left" valign="top" rowspan="1" colspan="1">8.0 (0.9)</td><td id="dom12439-ent-0040" align="left" valign="top" rowspan="1" colspan="1">8.0 (0.9)</td><td id="dom12439-ent-0041" align="left" valign="top" rowspan="1" colspan="1">8.0 (0.9)</td><td id="dom12439-ent-0042" align="left" valign="top" rowspan="1" colspan="1">8.1 (0.9)</td><td id="dom12439-ent-0043" align="left" valign="top" rowspan="1" colspan="1">7.7 (0.9)</td><td id="dom12439-ent-0044" align="left" valign="top" rowspan="1" colspan="1">7.9 (1.2)</td></tr><tr><td id="dom12439-ent-0045" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) BMI, kg/m<sup>2</sup>
</td><td id="dom12439-ent-0046" align="left" valign="top" rowspan="1" colspan="1">31.9 (6.4)</td><td id="dom12439-ent-0047" align="left" valign="top" rowspan="1" colspan="1">32.3 (6.4)</td><td id="dom12439-ent-0048" align="left" valign="top" rowspan="1" colspan="1">32.0 (6.5)</td><td id="dom12439-ent-0049" align="left" valign="top" rowspan="1" colspan="1">35.0 (7.8)</td><td id="dom12439-ent-0050" align="left" valign="top" rowspan="1" colspan="1">36.4 (6.8)</td><td id="dom12439-ent-0051" align="left" valign="top" rowspan="1" colspan="1">36.1 (9.1)</td></tr><tr><td id="dom12439-ent-0052" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) eGFR, ml/min/1.73&#x02009;m<sup>2</sup>
</td><td id="dom12439-ent-0053" align="left" valign="top" rowspan="1" colspan="1">87.0 (19.8)</td><td id="dom12439-ent-0054" align="left" valign="top" rowspan="1" colspan="1">88.3 (19.0)</td><td id="dom12439-ent-0055" align="left" valign="top" rowspan="1" colspan="1">88.8 (18.9)</td><td id="dom12439-ent-0056" align="left" valign="top" rowspan="1" colspan="1">71.3 (18.5)</td><td id="dom12439-ent-0057" align="left" valign="top" rowspan="1" colspan="1">80.9 (13.6)</td><td id="dom12439-ent-0058" align="left" valign="top" rowspan="1" colspan="1">75.0 (14.7)</td></tr></tbody></table><table-wrap-foot><fn id="dom12439-note-0001"><p>
<styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">eGFR</styled-content>, estimated glomerular filtration rate; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; s.d., standard deviation.</p></fn></table-wrap-foot></table-wrap><p id="dom12439-para-0009">From mean baseline serum uric acid levels of 5.3&#x02013;5.4&#x02009;mg/dl in the canagliflozin groups, both canagliflozin 100 and 300&#x02009;mg reduced serum uric acid levels by &#x0223c;13% (or 0.7&#x02009;mg/dl) relative to placebo at week&#x02009;26 in the overall cohort (Figure <xref rid="dom12439-fig-0001" ref-type="fig">1</xref>A). In patients with hyperuricaemia (mean baseline serum uric acid &#x0223c;8.5&#x02013;8.6&#x02009;mg/dl), the placebo&#x02010;adjusted percent reductions in serum uric acid with both doses of canagliflozin were generally similar to those observed in the overall cohort (Figure <xref rid="dom12439-fig-0001" ref-type="fig">1</xref>B). Furthermore, in the cohort with hyperuricaemia, the proportion of patients achieving serum uric acid levels&#x02009;&#x0003c;6&#x02009;mg/dl at week&#x02009;26 was 23.5% for canagliflozin 100&#x02009;mg and 32.4% for canagliflozin 300&#x02009;mg compared with 3.1% for placebo [placebo&#x02010;subtracted differences (95% CI)&#x02009;=&#x02009;20.4% (1.9, 38.9) and 29.3% (9.4, 49.1) with canagliflozin 100 and 300&#x02009;mg, respectively].</p><fig fig-type="Figure" xml:lang="en" id="dom12439-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Percent change in serum uric acid levels in (A) the overall pooled cohort and (B) the subset of patients with hyperuricaemia (baseline serum uric acid &#x02265;8&#x02009;mg/dl). The overall pooled cohort and the subset of patients with hyperuricaemia comprised the safety analysis set, regardless of rescue medication. Patients needed baseline and &#x02265;1 uric acid measurement at week&#x02009;26 for inclusion in this analysis. Data are least squares mean percent change from baseline (&#x000b1; standard error). <styled-content style="fixed-case">CANA</styled-content>, canagliflozin; <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">PBO</styled-content>, placebo.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-17-426-g001"><alt-text>DOM-12439-FIG-0001-c</alt-text></graphic></fig><sec id="dom12439-sec-0006"><title>Incidence of Gout and Kidney Stones</title><p id="dom12439-para-0010">The incidence rates of gout and kidney stones were similar between treatment groups in the overall pooled cohort. Gout was reported in 0.1, 0.2 and 0.5% of the patients in the canagliflozin 100&#x02009;mg, canagliflozin 300&#x02009;mg and placebo groups, respectively. Kidney stones were not reported in either of the canagliflozin&#x02010;treated groups, and occurred in 1 (0.2%) patient in the placebo group. In the cohort with hyperuricaemia, gout was reported in 1 patient in each of the canagliflozin 100&#x02009;mg, canagliflozin 300&#x02009;mg and the placebo groups (2.5, 2.6 and 2.7%, respectively). No patients in the cohort with hyperuricaemia reported kidney stones.</p></sec></sec><sec id="dom12439-sec-0007"><title>Discussion</title><p id="dom12439-para-0011">Canagliflozin decreased serum uric acid levels in patients with T2DM, including a subset of patients with hyperuricaemia. Furthermore, 20&#x02013;30% of patients with hyperuricaemia were able to achieve normal serum uric acid levels (&#x0003c;6&#x02009;mg/dl) with canagliflozin. Previous pharmacokinetic and pharmacodynamic studies have shown that this reduction in serum uric acid levels relates to an increased fractional excretion of uric acid during the first weeks of canagliflozin treatment <xref rid="dom12439-bib-0012" ref-type="ref">12</xref>. By week&#x02009;12, the total urinary uric acid excretion returned to near baseline levels, probably reflecting the persistent reduction in serum uric acid concentrations.</p><p id="dom12439-para-0012">The mechanism by which SGLT2 inhibitors reduce serum uric acid has not been established; however, it may possibly involve the renal SLC2A9 (GLUT9) transporter, which is known to exchange glucose for uric acid <xref rid="dom12439-bib-0013" ref-type="ref">13</xref>. Higher glucose concentrations in the urine attributable to canagliflozin treatment could lead to an increased exchange of uric acid in the apical membrane of tubular cells. Consequently, this would result in increased release of uric acid from blood into the urine, reducing serum uric acid levels <xref rid="dom12439-bib-0013" ref-type="ref">13</xref>. This potential mechanism is supported by evidence of trans&#x02010;stimulation of uric acid efflux with high glucose concentrations in Xenopus oocytes expressing SLC2A9b <xref rid="dom12439-bib-0014" ref-type="ref">14</xref>.</p><p id="dom12439-para-0013">In conclusion, both doses of canagliflozin reduced serum uric acid levels in patients with T2DM. Furthermore, up to 30% of patients with baseline hyperuricaemia and T2DM achieved normal serum acid levels with canagliflozin after 26&#x02009;weeks. Whether such changes have other beneficial effects on renal and/or cardiovascular complications will require evaluation in longer&#x02010;term studies.</p></sec><sec id="dom12439-sec-0009"><title>Conflict of Interest</title><p id="dom12439-para-0016">M. J. D. and A. T. are employees of Janssen Scientific Affairs LLC; U. V., C. V. D. and G. M. are employees of Janssen Research and Development LLC. All authors may own stock or stock options in Johnson &#x00026; Johnson. All authors participated in the analysis and interpretation of the data and the writing of the manuscript. All authors approved the final version of the manuscript.</p></sec></body><back><ack id="dom12439-sec-0008"><title>Acknowledgements</title><p id="dom12439-para-0014">This analysis was sponsored by Janssen Research &#x00026; Development, LLC. Editorial support was provided by Bilge Yoruk, PhD, of Excerpta Medica, and was funded by Janssen Scientific Affairs, LLC. Canagliflozin has been developed by Janssen Research &#x00026; Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation.</p><p id="dom12439-para-0015">This study was previously presented in poster form at the 74th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 13&#x02013;17 June 2014, and at the Annual Meeting of the American College of Clinical Pharmacy, Austin, TX, 12&#x02013;15 October 2014.</p></ack><ref-list content-type="cited-references" id="dom12439-bibl-0001"><title>References</title><ref id="dom12439-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12439-cit-0001">
<string-name>
<surname>Stenl&#x000f6;f</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cefalu</surname>
<given-names>WT</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>KA</given-names>
</string-name> et al. <article-title>Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise</article-title>. <source>Diabetes Obes Metab</source>
<year>2012</year>; <volume>15</volume>: <fpage>372</fpage>&#x02013;<lpage>382</lpage>.</mixed-citation></ref><ref id="dom12439-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12439-cit-0002">
<string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Solini</surname>
<given-names>A</given-names>
</string-name>. <article-title>SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects</article-title>. <source>Nat Rev Endocrinol</source>
<year>2012</year>; <volume>8</volume>: <fpage>495</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">22310849</pub-id></mixed-citation></ref><ref id="dom12439-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12439-cit-0003">
<string-name>
<surname>Usiskin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kline</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Fung</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mayer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Meininger</surname>
<given-names>G</given-names>
</string-name>. <article-title>Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results</article-title>. <source>Postgrad Med</source>
<year>2014</year>; <volume>126</volume>: <fpage>16</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">24918789</pub-id></mixed-citation></ref><ref id="dom12439-bib-0004"><label>4</label><mixed-citation publication-type="book" id="dom12439-cit-0004">
<string-name>
<surname>Becker</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Roessler</surname>
<given-names>BJ</given-names>
</string-name>. <chapter-title>Hyperuricemia and gout</chapter-title> In: <person-group person-group-type="editor"><name><surname>Scriver</surname><given-names>CR</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Beaudet</surname><given-names>AL</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Sly</surname><given-names>WS</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Valle</surname><given-names>D</given-names></name></person-group>, eds. <source>The Metabolic and Molecular Bases of Inherited Disease</source>. <edition>7th edn.</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>McGraw&#x02010;Hill</publisher-name>, <year>1995</year>; <fpage>1655</fpage>&#x02013;<lpage>1677</lpage>.</mixed-citation></ref><ref id="dom12439-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12439-cit-0005">
<string-name>
<surname>Ito</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mifune</surname>
<given-names>M</given-names>
</string-name> et al. <article-title>Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus</article-title>. <source>PLoS One</source>
<year>2011</year>; <volume>6</volume>: <fpage>e27817</fpage>.<pub-id pub-id-type="pmid">22125626</pub-id></mixed-citation></ref><ref id="dom12439-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12439-cit-0006">
<string-name>
<surname>Krishnan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pandya</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hariri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dabbous</surname>
<given-names>O</given-names>
</string-name>. <article-title>Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15&#x02010;year follow&#x02010;up study</article-title>. <source>Am J Epidemiol</source>
<year>2012</year>; <volume>176</volume>: <fpage>108</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">22753829</pub-id></mixed-citation></ref><ref id="dom12439-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12439-cit-0007">
<string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>L</given-names>
</string-name> et al. <article-title>Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta&#x02010;analysis</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <fpage>e78206</fpage>.<pub-id pub-id-type="pmid">24205159</pub-id></mixed-citation></ref><ref id="dom12439-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12439-cit-0008">
<string-name>
<surname>Schernthaner</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name> et al. <article-title>Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52&#x02010;week randomized trial</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>2508</fpage>&#x02013;<lpage>2515</lpage>.<pub-id pub-id-type="pmid">23564919</pub-id></mixed-citation></ref><ref id="dom12439-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12439-cit-0009">
<string-name>
<surname>Lavalle&#x02010;Gonz&#x000e1;lez</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Januszewicz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>J</given-names>
</string-name> et&#x02009;al. <article-title>Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial</article-title>. <source>Diabetologia</source>
<year>2013</year>; <volume>56</volume>: <fpage>2582</fpage>&#x02013;<lpage>2592</lpage>.<pub-id pub-id-type="pmid">24026211</pub-id></mixed-citation></ref><ref id="dom12439-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12439-cit-0010">
<string-name>
<surname>Forst</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Guthrie</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Goldenberg</surname>
<given-names>R</given-names>
</string-name> et al. <article-title>Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone</article-title>. <source>Diabetes Obes Metab</source>
<year>2014</year>; <volume>16</volume>: <fpage>467</fpage>&#x02013;<lpage>477</lpage>.<pub-id pub-id-type="pmid">24528605</pub-id></mixed-citation></ref><ref id="dom12439-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12439-cit-0011">
<string-name>
<surname>Reinders</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Jansen</surname>
<given-names>TL</given-names>
</string-name>. <article-title>Management of hyperuricemia in gout: focus on febuxostat</article-title>. <source>Clin Interv Aging</source>
<year>2010</year>; <volume>5</volume>: <fpage>7</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">20169038</pub-id></mixed-citation></ref><ref id="dom12439-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12439-cit-0012">
<string-name>
<surname>Sha</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Polidori</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name> et al. <article-title>Effect of the sodium glucose co&#x02010;transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>
<year>2014</year>; <volume>16</volume>: <fpage>1087</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">24939043</pub-id></mixed-citation></ref><ref id="dom12439-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12439-cit-0013">
<string-name>
<surname>Caulfield</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Munroe</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>D</given-names>
</string-name> et al. <article-title>SLC2A9 is a high&#x02010;capacity urate transporter in humans</article-title>. <source>PLoS Med</source>
<year>2008</year>; <volume>5</volume>: <fpage>e197</fpage>.<pub-id pub-id-type="pmid">18842065</pub-id></mixed-citation></ref><ref id="dom12439-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12439-cit-0014">
<string-name>
<surname>Chino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Samukawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sakai</surname>
<given-names>S</given-names>
</string-name> et al. <article-title>SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria</article-title>. <source>Biopharm Drug Dispos</source>
<year>2014</year>; <volume>35</volume>: <fpage>391</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">25044127</pub-id></mixed-citation></ref></ref-list></back></article>